Abstract: Objective To study the efficacy of bortezomib-combined chemotherapy in treatment of multiple myeloma and its effect on the levels of VEGF, IL-6 and IL-17. Methods Eighty inpatients were divided into routine group and bortezomib group. The drugs in the bortezomib group included thalidomide, bortezomib, doxorubicin and dexamethasone. VEGF, IL-6 and IL-17 were detected by ELISA and M protein was tested by agarose gel electrophoresis. Determination of globulin was performed by bromocresol green method, the number of bone marrow plasma cells （BMPCs） was examined by bone marrow puncture, and hemoglobin was detected by immunoturbidimetric assay. Results The levels of VEGF, IL-6 and IL-17 in the bortezomib group were significantly decreased compared with those in the routine chemotherapy group （P<0.05） after treatments. The levels of M protein, BMPCs and globulin were notably lower but the hemoglobin was higher in the bortezomib group than in the routine group （P<0.05）. The total therapeutic efficacy of bortezomib group was distinctively elevated. Additionally, bortezomib-combined therapy remarkably reduced the frequency of adverse reactions （P<0.05）. The levels of VEGF, IL-6 and IL-17 were found to be positively related to the severity of the disease. Conclusion Bortezomib-combined chemotherapy is effective and safe in treatment of multiple myeloma.

Key words: Multiple myeloma, M Protein, Plasma cells, Proinflammatory factors